



## Teleconference – October CEO Quarterly Update

Phosphagenics Limited (ASX: POH; OTCQX: PPGNY) invites interested parties to listen to the teleconference which was held on Friday, 6 October 2017.

The audio only webcast is now available for on-demand viewing for 12 months (expiring 17 October 2018) via this link:

<http://edge.media-server.com/m/go/phosphagenics-ceo-quarterly-update-20171006>

### Enquiries

Dr Ross Murdoch  
Phosphagenics Limited  
+61 3 9002 5000

### About Phosphagenics

Phosphagenics Limited is focused on developing and commercialising innovative Human Health, Animal Health and Personal Care products using its proprietary drug delivery system called TPM<sup>®</sup> (Targeted Penetration Matrix). TPM<sup>®</sup> is derived from Vitamin E using a unique, proprietary and patented process and has been proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Amongst its major projects, Phosphagenics' is developing TPM<sup>®</sup> enhanced patches, gels and injectable products for the human health market and is also developing TPM<sup>®</sup> to enhance the feed efficiency and health of livestock.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

[www.phosphagenics.com](http://www.phosphagenics.com)

---

#### Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

Unit A8, 2A Westall Road, Clayton VIC 3168 Australia

Tel: +61 (0)3 9002 5000 [www.phosphagenics.com](http://www.phosphagenics.com) Email: [info@phosphagenics.com](mailto:info@phosphagenics.com)